Sign inJoin waitlistJoin the waitlist

Katharine Price

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · ·

History

Mayo Clinic College of Medicine and Science
Present

Memorial Sloan Kettering Cancer Center
2006–2008
Internal Medicine
Mayo Clinic College of Medicine and Science
2003–2006
Mayo Clinic School of Medicine
1999–2003

Research

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2019 · 739 citations
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma
Journal of Clinical Oncology · 2019 · 195 citations
Current treatment options for metastatic head and neck cancer
Review · Current Treatment Options in Oncology · 2012 · First of 2 authors · Corresponding · 174 citations

Daniel Ma
36 papers · 1 as a resident
Eric Moore
33 papers
Daniel Price
30 papers · 1 as a fellow
AC
Ashish Chintakuntlawar
29 papers
Michelle Wittich
26 papers
RF
Robert Foote
26 papers
Katie Van Abel
24 papers · 8 as a fellow
Joaquin Garcia
23 papers · 7 as a resident
David Routman
21 papers · 5 as a resident
Jeffrey Janus
16 papers
Linda Yin
15 papers · 15 as a resident
Samip Patel
13 papers

Clinical trials

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2025–2028
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Site PI · Not yet recruiting · Phase 3
Corbus Pharmaceuticals Inc.
2026–2029
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2032